诺和诺德预计2026年销售额将下滑,引发抛售潮
Novo expects sales to fall in 2026, triggering selloff
生物技术与制药领域的最新动态
Novo expects sales to fall in 2026, triggering selloff
'Turning around the Titanic': How the incoming PBM reforms will transform CMS
What's driving health tech M&A
China startup AccurEdit raises $75M for gene editing therapies
Daiichi ends work on an ADC; Layoffs at GSK's R&D unit
Ultragenyx unwraps data that may be central to its gene therapy resubmission
Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months
AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo
Carbon Health files for bankruptcy, seeking to sell or restructure
First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?
New CagriSema data show improvement over semaglutide
GSK returns rights to Wave's RNA editing program for AATD
Spring Health acquires Alma, expanding insurance reach in virtual mental health
Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT
FDA rejects Aquestive's allergy drug over packaging issues
FDA opens submissions for PreCheck program to speed up US factory builds
SanegeneBio licenses RNAi candidate to Genentech for $200M upfront
Pharming’s immunodeficiency drug gets CRL for use in younger patients
European law changes mean drugmakers may have to grapple with generic competition sooner